If approved per MSD's filing, the new version would become an alternative to IV Keytruda for the full range of Keytruda indications, which span dozens of different cancers and treatment lines.

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

Oh This Is Us (IRE) 16-1 (9-9) In touch, headway over 2f out, soon chasing leaders, every chance inside final furlong, kept on, 4th of 14, 1l behind Sanaadh (8-6) at Newcastle 7f hcp (2) pol in ...

Add a description, image, and links to the cve-2025-1771 topic page so that developers can more easily learn about it.